�鶹��Ƶ

A groundbreaking has been accepted for publication in JAMA Oncology. The technology tested in the trial was co-developed by Gary Koski, Ph.D., professor in �鶹��Ƶ’s Department of Biological Sciences in Kent, Ohio, and , chair and senior member in the Moffitt Cancer Center’s Department of Breast Oncology in Tampa, Florida. The study focuses on a new treatment approach that aims to harness the body’s immune system to enhance patient responses and reduce the need for conventional chemotherapy and its associated toxicities.

The trial involved 12 patients with locally advanced stage I-III HER2 breast cancer. This research builds upon insights gained from previous studies funded by a Department of Defense Breakthrough Award research grant.

“We are hopeful that we will be able to use this new immunotherapy instead of chemotherapy, or at least dramatically reduce the need for chemotherapy, for all types of breast cancer,” Czerniecki said.

The immunotherapy leverages dendritic cells, critical components of the immune system that normally identify infection and mobilize other elements of immunity to repel a microbial attack. By removing some of these dendritic cells from the body, biochemically reprogramming them for anti-cancer activity and injecting them directly into breast tumors, the researchers could trigger a powerful, organized immune system attack on the cancer. This led to the significant shrinkage of tumors before standard chemotherapy was administered.

Eight out of the 12 patients demonstrated at least a 50% reduction in tumor volume after just six weeks of immunotherapy. This treatment produced only minimal side effects, primarily mild flu-like symptoms, compared with the severe side effects often associated with traditional chemotherapy.

“These exciting results are the culmination of nearly 30 years of collaborative research between my laboratory and Dr. Czerniecki’s,” Koski said.

The researchers have already begun a larger phase two trial to test higher doses of the immunotherapy, further exploring the potential effectiveness of this new technology.

The published clinical trial was supported by the Moffitt Breast Cancer Research Fund, the Don Shula Foundation and donations from the organization, which has raised approximately $7 million over the last decade to support this innovative cancer research. This unique funding model allows patients to directly contribute to advancements in treatments that may benefit them and others in the future.

About Gary Koski and Brian Czerniecki

Koski has been teaching at �鶹��Ƶ, an R1 top-tier research university, since 2010 and is a recipient of �鶹��Ƶ’s Distinguished Teaching Award. He earned his zoology pre-med degree from �鶹��Ƶ before getting a Ph.D. in immunology and infectious disease at Johns Hopkins University. After receiving his doctorate, he conducted research at the National Institutes of Health, University of Pennsylvania Medical School and Cleveland Clinic. He currently teaches Immunology and Principles of Infectious Disease and pursues research in the areas of immunology, cancer immunotherapy and dendritic cell biology.

For more information about �鶹��Ƶ’s Department of Biological Sciences, visit www.kent.edu/biology.

Czerniecki received his Bachelor of Science in Biochemistry from the University of Maine and his Doctor of Medicine from the University of Medicine and Dentistry of New Jersey (UMDNJ), Robert Wood Johnson Medical School, and his Ph.D. from UMDNJ-Robert Wood Johnson and Rutgers University. He completed his general surgical residency at Ohio State University and was Surgical Oncology Fellow at the National Cancer Institute prior to his position at the University of Pennsylvania, Philadelphia. While at the University of Pennsylvania, Dr. Czerniecki served as professor of surgery, Perelman School of Medicine; attending surgeon, Department of Surgery, Hospital of the University of Pennsylvania; and co-director of the Rena Rowan Breast Center–Recruitment and Center Expansion. His research interests focus on dendritic cell biology and interactions with T cells. He has developed dendritic cell vaccines for the treatment of cancer. He is known nationally for his contribution to the development of sentinel lymph node mapping, a procedure for determining the spread of cancer into lymph nodes that is less invasive than diagnostic surgery.

For more information about Czerniecki and Moffitt Cancer Center, visit .

# # #

Photo Caption: 
The top image is Gary Koski, Ph.D., professor (left) and Carissa Lepore, Ph.D., a lab team member and research scientist in the Department of Biological Sciences at �鶹��Ƶ, in Koski's Cunningham Hall laboratory on the Kent Campus.

Media Contacts: 
Jim Maxwell, JMAXWEL2@kent.edu, 330-672-8028
Emily Vincent, evincen2@kent.edu, 330-672-8595